Study to Evaluate drug GS-8588 in People With HIV-1 Who are Virologically Suppressed on Antiretroviral Therapy

The research study is being conducted to test an experimental drug, GS-8588, for the treatment and remission of human immunodeficiency virus (HIV) infection. GS-8588 is a special type of protein, called an antibody, that helps the immune system bring your immune cells closer to the cells infected with HIV. Finding ways to target and destroy the hidden HIV in body cells is a major challenge facing HIV researchers who are exploring different strategies to find a potential cure for HIV. Participants will be asked to complete the following research procedures: • Be randomized (such as with the flip of a coin) to one of the study groups. • Receive either a placebo or the study drug, GS-8588. • Be asked to attend at least 9 study visits over the course of about 100 days. • Have at least 1 overnight stay of 5 consecutive (in a row) days/4 nights. • Refrain from using certain medications. • Have approximately 21 blood draws and approximately 8 urine samples taken. Participation will last for approximately 100 days. Participants will be paid $75 for completing each screening visit. For the visit from (Day -1 to Day 3, the visit from Day 14 to Day 17, the visit on Day 29, the visit on Day 43 and the visit on Day 57, participants will be paid $400 each time, since these will be longer in-patient visits. For all other scheduled study visit thereafter up to Day 155, participants will be paid $75 for every visit attended. The total amount for attending all expected visits is $3500.

You may be eligible for this study if you meet the following criteria:

• Conditions: HIV
• Age: 18 years - 99 years
• Gender: All